Skip to main content Accessibility help

Antibiotic Cycling and Marketing Into the 21st Century: A Perspective From the Pharmaceutical Industry

  • Bruce S. Lavin (a1)


Before the development of the first antimicrobial agents, bacteria already had demonstrated an ability to adapt to stress in the environment, resulting in the development of resistance that often makes the prevailing antibiotic treatment ineffective. The response to antimicrobial resistance in the medical community has been to use new or alternative antibiotics not previously used against the resistant bacteria. The pharmaceutical industry has responded to the resistance problem by producing newer antibiotics, either as modifications of currently existing compounds or as combinations of compounds that may inhibit or bypass the bacterial resistance mechanisms. The development of new antibiotics is a lengthy and costly process. To be successful, the pharmaceutical industry must anticipate the changing needs of the medical community, as well as the dynamic process of antimicrobial resistance. The marketing of new antimicrobial agents must be adaptable to the potential environmental pressures that induce bacterial resistance in order to ensure the longevity of the agents.


Corresponding author

Anti-Infectives, US Medical Affairs, Rhone-Poulenc Rorer Pharmaceuticals, 500 Areola Rd 4C61, Collegeville, PA 19426-0998


Hide All
1.Billstein, SA. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Antimkrob Agents Chemother 1994;38:26792682
2.Edmond, MB, Wallace, SE, McClish, DK, Pfaller, MA, Jones, RN, Wenzel, RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239244.
3.Jones, RN, Marshall, SA, Pfaller, MA, Wilke, WW, Hollis, RJ, Erwin, ME, et al. Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997;29:95102.
4.Jones, RN, Ballow, CH, Biedenbach, DJ, Deinhart, JA, Schentag, JJ. Antimicrobial activity of qujmupristm-dalfopristin (RP 59500, Synercid) tested over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998;31:437451.
5.Hruby, DE. Bacterial adherence as a novel target for anti-infective development. In: Proceedings of Third International Antibacterial Drug Discovery & Development Summit; Princeton, NJ; March 8-9, 1999.
6.Gaynes, RThe impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757765.
7.Pharmaceutical Manufacturers Association. Pocket Facts. Washington, DC: PMA; 1993.
8.Pechere, JC. Current and future management of infections due to methi-cillin-resistant staphylococci infections: the role of quinupristin/dalfo-pristin. JAntimicrobial Chemother 1999;44(suppl A):1118.
9.Quale, J, Landman, D, Saurino, G, Atwood, E, DiTore, V, Patel, K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infed Dis 1996;23:10201025.
10.Hershow, RC, Khayr, WF, Schreckenberger, PC. Ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: associated factors and resistance to other antibiotics. AmJTher 1998;5:213220.
11.Chin, G, Marx, J. Resistance to antibiotics. Science 1994;264:359393.
12.Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Disease Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275291.
13.McGowan, JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994;15:478483.
14.Goodman, D. Workshop to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. JAMA 1996;275:12321240.
15.Gerding, DN, Larson, TA, Hughes, RA, Weiler, M, Shanholtzer, C, Peterson, LRAminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimkrob Agents Chemother 1991;35:12841290.
16.Dominguez, E. Antibiotic cycling helps hospitals cope with resistance. ASM News 1996;62:457.
17.Schentag, JJ, Ballow, CH, Fritz, AL, Paladino, JA, Williams, JD, Cumbo, TJ, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993;16:255264.
18.Kollef, MH, Vlasnik, J, Sharpless, L, Pasque, C, Murphy, D, Fraser, V. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:10401048.
19.Seppala, H, Klaukka, T, Vuopio-Varkila, J, Muotiala, A, Helenius, H, Lager, K, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441446.


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed